Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

J. Menczer, G. Ben-Baruch, S. Rizel, H. Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependant drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.

Original languageEnglish
Pages (from-to)316-318
Number of pages3
JournalEuropean Journal of Gynaecological Oncology
Volume13
Issue number4
StatePublished - 1992
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study'. Together they form a unique fingerprint.

Cite this